All In Biotech

Drug Trial Radar · NCT06378229

Psilocybin for Hospitalized Patients with Treatment-resistant Depression

Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

May 21, 2024

Primary completion

Mar 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
University Hospital, GhentAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Filament Health Corp.
First posted
Apr 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression.

Conditions

  • Treatment Resistant Depression

Interventions

  • PsilocybinDrug

    A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (PEX010).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and type of Treatment-Emergent Adverse EventsTime frame: 18 weeks
  2. Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: 18 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ghent University Hospital

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.